Twin City Private Wealth LLC Increases Stock Position in Sanofi $SNY

Twin City Private Wealth LLC boosted its stake in Sanofi (NASDAQ:SNY) by 20.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,837 shares of the company’s stock after acquiring an additional 2,365 shares during the period. Twin City Private Wealth LLC’s holdings in Sanofi were worth $668,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in SNY. Brighton Jones LLC raised its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock valued at $1,344,000 after acquiring an additional 13,358 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Sanofi by 15.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 133,604 shares of the company’s stock valued at $7,260,000 after acquiring an additional 18,274 shares in the last quarter. Private Trust Co. NA raised its holdings in Sanofi by 19.8% in the first quarter. Private Trust Co. NA now owns 4,220 shares of the company’s stock valued at $234,000 after acquiring an additional 697 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its holdings in Sanofi by 9.9% in the first quarter. Checchi Capital Advisers LLC now owns 13,080 shares of the company’s stock valued at $725,000 after acquiring an additional 1,180 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Stock Down 0.7%

Shares of NASDAQ:SNY opened at $50.58 on Friday. The stock has a market capitalization of $124.20 billion, a price-to-earnings ratio of 11.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company’s fifty day moving average is $48.69 and its two-hundred day moving average is $49.55. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.60 by $0.10. The business had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 earnings per share. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.